Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4+ T cells

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7195-7199

  Voo, Kui Shin ^a,b   Fu, Tihui ^a,b   Heslop, Helen E ^a,b   Brenner, Malcolm K ^a,b   Rooney, Cliona M ^a,b   Wang, Rong Fu ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL NUCLEUS ANTIGEN; COMPLEMENTARY DNA; EBNA1 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; HLA DP ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DNA SEQUENCE; EPISOME; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; MELANOMA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS CARCINOGENESIS;

ALLELES; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BURKITT LYMPHOMA; CD4-POSITIVE T-LYMPHOCYTES; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HLA-DP ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037115633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kieff, E. Epstein-Barr virus-increasing evidence of a link to carcinoma. N. Engl. J. Med., 333: 724-726, 1995.
2. Rickinson, A. B., and Moss, D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol., 15: 405-431, 1997.
3. Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H., and Rickinson, A. B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J., 6: 2743-2751, 1987.
4. Khanna, R., Moss, D. J., and Burrows, S. R. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev., 170: 49-64, 1999.
5. Kalams, S. A., and Walker, B. D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med., 188: 2199-2204, 1998.
6. + T cells. Curr. Opin. Immunol., 10: 444-449, 1998.
7. + T cells in antitumor immunity. Trends Immunol., 22: 269-276, 2001.
8. Munz, C., Bickham, K. L., Subklewe, M., Tsang, M. L., Chahroudi, A., Kurilla, M. G., Zhang, D., O'Donnell, M., and Steinman, R. M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med., 191: 1649-1660, 2000.
9. + T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol., 75: 3740-3752, 2001.
10. Leen, A., Meij, P., Redchenko, I., Middeldorp, J., Bloemena, E., Rickinson, A., and Blake, N. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper I responses. J. Virol., 75: 8649-8659, 2001.
11. Roskrow, M. A., Suzuki, N., Gan, Y., Sixbey, J. W., Ng, C. Y., Kimbrough, S., Hudson, M., Brenner, M. K., Heslop, H. E., and Rooney, C. M. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood, 91: 2925-2934, 1998.
12. Heslop, H. E., Perez, M., Benaim, E., Rochester, R., Brenner. M. K., and Rooney, C. M. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J. Clin. Apheresis, 14: 154-156, 1999.
13. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA-DP4 allele: Association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA, 98: 3964-3969, 2001.
14. Wang, R. F., and Rosenberg, S. A. Human tumor antigens for cancer vaccine development. Immunol. Rev., 170: 85-100, 1999.
15. Frappier, L., and O'Donnell, M. Overproduction, purification, and characterization of EBNAI, the origin binding protein of Epstein-Barr virus. J. Biol. Chem., 266: 7819-7826, 1991.
16. Wang, R-F., Johnston, S. L., Zeng, G., Schwartzentruber, D. J., and Rosenberg, S. A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol., 161: 3596-3606, 1998.
17. Tellam, J., Sherritt, M., Thomson, S., Tellam, R., Moss, D. J., Burrows, S. R., Wiertz, E., and Khanna, R. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem., 276: 33353-33360, 2001.
18. Khanna, R., Burrows, S. R., Steigerwald-Mullen, P. M., Thomson, S. A., Kurilla, M. G., and Moss, D. J. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance. Virology, 214: 633-637, 1995.
19. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol., 165: 1153-1159, 2000.
20. Wang, R-F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science (Wash. DC), 284: 1351-1354, 1999.
21. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M., Boon, T., and van der Bruggen, P. Identification of MAGE-3 Epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med., 189: 767-778, 1999.
22. + T cells. Cancer Res., 62: 213-218, 2002.
23. Paludan, C., Bickham, K., Nikiforow, S., Tsang, M. L., Goodman, K., Hanekom, W. A., Fonteneau, J. F., Stevanovic, S., and Munz, C. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol., 169: 1593-1603, 2002.